IC
RLMD icon

Ikarian Capital’s Relmada Therapeutics RLMD Stock Holding History

Ikarian Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
2,148,359
-540,000
-20% -$3.77M 1.6% 15
2026
Q1 		$18.7M Sell
2,688,359
-380,000
-12% -$1.8M 1.52% 15
2025
Q4 		$14.8M Buy
3,068,359
+1,225,299
+66% +$4.11M 1.16% 25
2025
Q3 		$3.7M Buy
1,843,060
+1,802,790
+4,477% +$1.73M 0.37% 72
2025
Q2 		$24.2K Hold
40,270
– – ﹤0.01% 132
2025
Q1 		$10.9K Hold
40,270
– – ﹤0.01% 160
2024
Q4 		$20.9K Sell
40,270
-99
-0.2% -$241 ﹤0.01% 163
2024
Q3 		$131K Hold
40,369
– – 0.02% 140
2024
Q2 		$121K Hold
40,369
– – 0.02% 108
2024
Q1 		$188K Hold
40,369
– – 0.02% 127
2023
Q4 		$167K Hold
40,369
– – 0.02% 125
2023
Q3 		$121K Sell
40,369
-25,122
-38% -$74.6K 0.01% 126
2023
Q2 		$161K Hold
65,491
– – 0.03% 114
2023
Q1 		$148K Hold
65,491
– – 0.03% 108
2022
Q4 		$229K Buy
+65,491
New +$575K 0.06% 72
2022
Q2 		– Sell
-21,801
Closed -$476K – 194
2022
Q1 		$588K Buy
21,801
+1,058
+5% +$21.9K 0.08% 123
2021
Q4 		$467K Hold
20,743
– – 0.07% 131
2021
Q3 		$544K Sell
20,743
-279,464
-93% -$7.48M 0.04% 183
2021
Q2 		$9.61M Buy
300,207
+10,000
+3% +$347K 0.78% 36
2021
Q1 		$10.2M Buy
+290,207
New +$10.2M 0.34% 69
2020
Q2 		– Sell
-55,172
Closed -$1.88M – 205
2020
Q1 		$1.88M Buy
+55,172
New +$2.22M 0.14% 97

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital's RLMD Position: Q2 2026 in Review

Ikarian Capital reduced its Relmada Therapeutics (RLMD) stake by 20% in Q2 2026, selling an estimated $3.77M and leaving 2,148,359 shares worth $14.9M. The position accounts for 1.6% of the portfolio, ranked #15.

Ikarian Capital first reported a position in RLMD in Q1 2020 and has held it in 21 quarters since. The position peaked at $18.7M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Ikarian Capital held 2,148,359 shares of Relmada Therapeutics worth $14.9M as of Q2 2026.
  • Ikarian Capital sold 540,000 Relmada Therapeutics shares in Q2 2026, an estimated $3.77M.
  • Relmada Therapeutics made up 1.6% of Ikarian Capital's portfolio in Q2 2026, its #15 holding.
  • Ikarian Capital first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Ikarian Capital's Relmada Therapeutics position peaked at $18.7M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.